-
WHY ARE HTA REVIEWERS STILL HUNTING FOR CODING ERRORS? AN AI VALIDATOR AGENT AS A FIRST-LINE QA LAYER FOR SUBMITTED MODELS
Aug 11, 2026, 17:16 PM -
EXPLORING THE BURDEN OF CHRONIC INDUCIBLE URTICARIA AND THE MEANINGFULNESS OF TREATMENT USING IN-TRIAL INTERVIEWS
Aug 11, 2026, 17:16 PM -
TREATMENT PATTERNS AMONG FGFR-POSITIVE METASTATIC UROTHELIAL CARCINOMA PATIENTS: A NORSTELLALINQ CLAIMS AND EHR ANALYSIS
Aug 11, 2026, 17:16 PM -
HIGH-DOSE INFLUENZA VACCINATION IN OLDER ADULTS: A COST-EFFECTIVENESS REVIEW INCORPORATING BROADER COMPLICATIONS AND HOSPITALIZATION OUTCOMES
Aug 11, 2026, 17:16 PM -
AN ACTUARIAL APPROACH TO MANAGED ACCESS AGREEMENTS: ADDRESSING SURROGATE ENDPOINTS, DATA SILOS, AND LEGAL PROCUREMENT CONSTRAINTS IN RESISTANT HYPERTENSION
Aug 11, 2026, 17:16 PM -
BUDGET IMPACT OF INTRODUCING A SECOND BEVACIZUMAB BIOSIMILAR FOR METASTATIC COLORECTAL CANCER IN MOROCCO: A FIVE-YEAR ANALYSIS FROM THE MANDATORY HEALTH INSURANCE PERSPECTIVE
Aug 11, 2026, 17:16 PM -
IMPLEMENTATION OF MULTILEVEL DATA QUALITY METRICS IN AN INTERNATIONAL REGISTRY FOR RARE ENDOCRINE CONDITIONS
Aug 11, 2026, 17:16 PM -
PAYER AND REGULATOR EVIDENCE REQUIREMENTS FOR CLINICAL OUTCOME ASSESSMENTS: A COMPARATIVE REVIEW OF US, ENGLISH, EUROPEAN AND CANADIAN GUIDANCE
Aug 11, 2026, 17:16 PM -
THROMBOLYTIC TREATMENT, THROMBECTOMY AND OUTCOMES OF ACUTE PULMONARY EMBOLISM - REAL-WORLD DATA FROM 2014 TO 2023 IN GERMANY
Aug 11, 2026, 17:16 PM -
THE CLINICAL, ECONOMIC, AND OPERATIONAL BENEFITS OF IMPLEMENTING THE BUNDLED HIV, HEPATITIS B, AND SYPHILIS DETERMINE ANTENATAL CARE PANEL FOR PREGNANT WOMEN IN RWANDA
Aug 11, 2026, 17:16 PM -
ECONOMIC EVALUATION OF SPARSENTAN VERSUS TARGETED-RELEASE FORMULATION BUDESONIDE IN PATIENTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY IN AUSTRIA
Aug 11, 2026, 17:16 PM -
MANAGED ENTRY AGREEMENTS FOR CELL AND GENE THERAPIES IN GERMANY: CURRENT LANDSCAPE AND POSSIBLE MITIGATION STRATEGY FOR MOST-FAVORED-NATION PRICING
Aug 11, 2026, 17:16 PM -
ONE HTA PROCESS, MANY PAYERS: A CROSS-SYSTEM MULTICRITERIA NETWORK FOR HIGH-COST ONCOLOGY IN A SEGMENTED HEALTH SYSTEM (PERU'S RENETSA, 2020-2026)
Aug 11, 2026, 17:16 PM -
WHICH EVIDENCE COUNTS? REAL-WORLD DATA, SURROGATE ENDPOINTS, AND SINGLE-ARM TRIALS IN EU JOINT CLINICAL ASSESSMENT
Aug 11, 2026, 17:16 PM -
EXTERNAL VALIDATION OF THE ADA DIABETES RISK SCORE FOR POPULATION-LEVEL DIABETES SCREENING IN THE UNITED ARAB EMIRATES
Aug 11, 2026, 17:16 PM -
USE OF PRIMARY CARE RESOURCES AMONG PATIENTS WHO ARE FREQUENT VISITORS (ONE YEAR, TWO YEARS, AND PERSISTENT) AND NON-FREQUENT VISITORS IN THIN® PRIMARY CARE DB IN BELGIUM AND SPAIN DURING 2023 TO 2025 PERIOD
Aug 11, 2026, 17:16 PM -
GLOBAL ECONOMIC AND HUMANISTIC BURDEN OF SEVERE HYPERTRIGLYCERIDEMIA: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
UNSTRUCTURED CLINICAL NOTES AS A SOURCE OF NON-SMALL CELL LUNG CANCER (NSCLC) BIOMARKER INFORMATION BEYOND STRUCTURED DATA: EVIDENCE FROM NORSTELLALINQ REAL-WORLD DATA UNSTRUCTURED CLINICAL NOTES AS A SOURCE OF NON-SMALL CELL LUNG CANCER (NSCLC...
Aug 11, 2026, 17:16 PM -
USE OF EXTERNAL DATA IN ONCOLOGY AND RARE DISEASE: A SCOPING REVIEW OF EMA SUBMISSIONS (2015-2025)
Aug 11, 2026, 17:16 PM -
PATIENT-REPORTED EXPERIENCES OF TENOSYNOVIAL GIANT CELL TUMOR (TGCT) SYMPTOMS IN THE MANEUVER PHASE 3 TRIAL: INSIGHTS FROM EXIT INTERVIEWS
Aug 11, 2026, 17:16 PM
